Since its introduction in 1977, Percutaneous Coronary Intervention (PCI) 
. underwent successful angioplasty with stenting to LAD. Left main coronary artery was engaged with Judkin's left guide catheter (3.5, 6F size). Initial angiographic views showed the lesion in LAD had already transformed from 80% stenosis to sub-total occlusion.
So an ACS 0.014"X190 cm intermediate PTCA guide wire was chosen for crossing the lesion. With a 1.5x15 mm balloon support (Sprinter balloon, Medtronic, USA) the lesion was crossed and the tip of the guide wire was parked in distal LAD. The lesion was inflated by the PTCA balloon at 12 to18 atmospheric pressure by multiple inflations. The LAD lesion was thus opened up. However, it was a long lesion with considerable residual stenosis. Hence 2 stents were used to cover the whole lesion. Distally a 2.5x25mm Flyer stent (bare metal, Atrium, USA) was deployed; proximally a 2.5x19mm Flyer stent was deployed overlapping with the previous stent. The overlapped junction was inflated at higher pressure for good apposition. The result was a gratifying TIMI III flow to distal vessel with no residual stenosis and no dissection.
was quite asymptomatic, haemodynamically stable and happy. 
Discussion

Conclusion:
PCI is an important treatment modality for cardiac patients. Considering the importance of the procedure we hereby are proudly reporting the first regular case of Percutaneous coronary intervention (PCI) done in Dhaka Medical College Hospital. Patient was heparinised with low molecular weight heparin Enoxaparin at a dose of 1 mg/kg body weight intravenously at the beginning of the procedure. During the procedure intra-coronary GTN (nitrate) at a dose of 100-200 microgram was used repeatedly to prevent vasospasm. After the procedure patient was kept in CCU (coronary care unit) for 24 hours. The vascular access sheaths were removed after 4 hours. Patient was kept on oral nitrate, diltiazem, dual anti platelets (both aspirin and clopidogrel), and statin (atorvastatin 40 mg per day). Injection Enoxaparin was continued at a dose of 60 mg B.D. subcutaneously for 3 days to prevent sub-acute stent thrombosis. Patient was discharged on the 4 th day. At follow up 7 days later, patient
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